Biotechnology & CRO

Chimera Biotec develops and markets ultra-sensitive ligand-binding assays for pharmacokinetic, pharmacodynamic and biomarker applications.
The services utilize the proprietary Imperacer® (immuno-PCR) technology.

Imperacer® quantitatively detects molecules such as proteins, peptides, biomarkers and metabolites in complex biological samples while extending the dynamic range of any immunoassay by orders of magnitude.

Chimera Biotec

What we offer

Chimera Biotec offers user specific services as well as off-the-shelf products based on Imperacer® technology and platform.

The Immuno-PCR based Imperacer ® technology combines the well-established ELISA methodology with the signal amplification power of the PCR. As a consequence an approx. 100 to 1,000-fold gain in sensitivity compared to conventional ELISA can be achieved.

We assist customers and the scientific community in the detection and quantification of targets, like antibodies, autoantibodies, biomarkers and peptide drugs which occur in ultra-low concentrations.

What we are looking for

Challenging discussions on topics regarding ligand-binding assays.
Cooperation opportunities in assay development project in R&D.

Collaboration sought

  • Research & Development

Responsible

Ms Dr. Beena Punnamoottil

Senior Project Manager

back to list